Premium
Bioavailability of a generic of the immunosuppressive agent mycophenolate mofetil in pediatric patients
Author(s) -
GonzálezRamírez Rodrigo,
GonzálezBañuelos Jessica,
Villa María de la Salud,
Jiménez Braulio,
GarcíaRoca Pilar,
CruzAntonio Leticia,
CastañedaHernández Gilberto,
Medeiros Mara
Publication year - 2014
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12311
Subject(s) - bioavailability , mycophenolate , innovator , medicine , mycophenolic acid , pharmacokinetics , pharmacology , transplantation , drug , intellectual property , computer science , operating system
The use of generic immunosuppressive agents is controversial, especially for the treatment of pediatric patients, as information on the bioavailability of generic immunosuppressants in children is particularly scarce. The aim of the study was to compare the bioavailabilities of two products containing mycophenolate mofetil, the innovator and a generic, in children. Pediatric patients with end‐stage renal disease on the waiting list for renal transplantation received a single oral dose of mycophenolate mofetil as either the innovator product (CellCept ® , Roche) or the generic (Tevacept ® , Teva Pharmaceuticals). A nine point pharmacokinetic profile was obtained. Mycophenolic acid concentration was quantitated in plasma by HPLC , plasma concentration‐against‐time curves were constructed, and bioavailability parameters were determined. Pharmaceutical quality analysis of both formulations, including drug content and dissolution profile, was also performed. There were no statistically significant differences between formulations in bioavailability parameters. Interindividual variability was very important, but individual values of AUC, an indicator of the extent of drug absorption, were within the same range for both formulations. The two formulations exhibited similar drug content and dissolution profiles, as well as comparable mycophenolic acid plasma levels in an end‐stage renal failure population.